CTOs on the Move

FEI Systems

www.feisystems.com

 
FEI Systems is a leading IT company specializing in Federal and Local Government data system solutions, and for the past decade we have maintained a leading position in providing programming and consulting services in our primary areas of expertise- Behavioral Health Data Systems, and Clinical Trials Software Solutions for institutional systems of care. At the heart of our success you`ll find a talented team of experts who have helped our customers bridge the gap between the business needs of their organization, and the application of technologies required to successfully manage them.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.feisystems.com
  • 9755 Patuxent Woods Drive Suite 300
    Columbia, MD USA 21046
  • Phone: 443.270.5100

Executives

Name Title Contact Details

Similar Companies

Iovance Biotherapeutics

Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California.

Precision Diagnostics

Precision Diagnostics, a leader in clinical laboratory testing and medication adherence monitoring, is transforming healthcare through the delivery of comprehensive, insightful clinical data that can help improve patient outcomes and manage costs. Spec...

Vibalogics

Vibalogics is a CDMO offering process development, manufacturing, testing, and fill-finish services to innovators developing revolutionary virotherapy products.

Accera div Nestle Corp

Accera div Nestle Corp is a Broomfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elevation Oncology

Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor`s unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.